# Acer Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acer-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Newton, US
- Website: www.acertx.com
- Total disclosed funding: $12M
- Latest round: Series B (May 6, 2016)
- Investors on record: 2

## About

Acer Therapeutics Inc. is a US-based biopharmaceutical company focused on developing and commercializing innovative therapies for serious rare diseases with unmet medical needs.Founded in 2013 and headquartered in Newton, US, Acer Therapeutics Inc. specializes in therapies for rare and life-threatening diseases. The company has engaged in eight deals, with its most recent funding round being a Private Placement/Follow on in March 2022, raising USD 2.68 mn, which is also the total amount raised to date. Chris Schelling serves as both the founder and CEO.Acer Therapeutics actively acquires, develops, and commercializes therapies for serious rare diseases. Its primary products include OLPRUVA™ (sodium phenylbutyrate) for Urea Cycle Disorders and EDSIVO™ (celiprolol) for vascular Ehlers-Danlos syndrome. These products are marketed in the United States, catering to patients with rare conditions and their healthcare providers, as well as exploring additional investigational candidates targeting conditions like Maple Syrup Urine Disease.In 2021, Acer Therapeutics generated revenue of USD 1.26 mn. The company focuses on B2B sales of its approved products through partnerships with healthcare providers and institutions, which are essential for funding ongoing research and development.Acer Therapeutics plans to utilize its recent funding from the March 2022 Private Placement/Follow on to support the development of new products and expand its market presence. Specific future initiatives include the launch of additional therapies aimed at rare diseases, though no specific release dates are provided. The company is also targeting expansion into broader geographic markets to enhance accessibility for its patient base.

## Funding rounds

- Series B, May 6, 2016, $8.2M — TVM Capital Life Science, Bukwang Pharmaceutical Co., Ltd.
- Series A, Jul 1, 2015, $4.1M — TVM Capital Life Science

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series B
- Bukwang Pharmaceutical Co., Ltd. — Series B